Janssen
Corporate brand
UnclaimedJanssen Canada is the Canadian pharmaceutical business of Johnson & Johnson, now operating under the Johnson & Johnson Innovative Medicine identity.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Janssen Canada is the Canadian pharmaceutical organization historically associated with the Janssen brand and currently operating under the Johnson & Johnson Innovative Medicine identity. The Canadian business is carried on by Janssen Inc., an Ontario corporation headquartered in Toronto. It develops, registers, commercializes, and supports prescription medicines and related healthcare services for patients and healthcare professionals in Canada. The business is part of Johnson & Johnson, whose pharmaceutical operations were historically grouped under the Janssen Pharmaceutical Companies of Johnson & Johnson. The name Janssen derives from Dr. Paul Janssen, the Belgian physician, pharmacologist, and pharmaceutical researcher whose company Janssen Pharmaceutica joined Johnson & Johnson in 1961. Under Johnson & Johnson ownership, the Janssen organization developed into a multinational research-based pharmaceutical network with operations in more than 150 countries. Its Canadian presence has operated for more than five decades and has included sales, medical affairs, regulatory, market access, patient-support, clinical-trial, and public-policy activities. Janssen Canada is not a food or consumer-staples company. Its principal business is innovative medicine, with a portfolio centered on serious and complex diseases. The Canadian organization has identified oncology, immunology, neuroscience, cardiovascular and metabolic disease, pulmonary hypertension, communicable diseases, and related specialty-care areas as important fields of activity. Its products include biologic medicines, small-molecule pharmaceuticals, specialty therapies, and advanced treatments such as CAR-T cell therapy. The Canadian product catalogue has included brands such as DARZALEX, ERLEADA, IMBRUVICA, STELARA, TREMFYA, SPRAVATO, CONCERTA, ZYTIGA, RYBREVANT, CARVYKTI, and other medicines subject to Canadian regulatory authorization and commercial availability. The Canadian operation generally functions as a commercial, medical, regulatory, and market-access organization rather than as a domestic manufacturing base. Johnson & Johnson’s Canadian supply-chain reporting states that Janssen Inc. provides sales and marketing support for products manufactured by Johnson & Johnson and its partners internationally and imported into Canada. The organization also works with Health Canada, provincial drug plans, hospitals, clinicians, professional bodies, patient organizations, and payers to support regulatory review, reimbursement, appropriate use, and patient access. A major strategic change occurred during the 2020s. Johnson & Johnson began consolidating its corporate identity around the Johnson & Johnson name and announced that the Janssen pharmaceutical segment would progressively be renamed Johnson & Johnson Innovative Medicine. In Canada, the transition was publicly presented in 2024, while the legal entity Janssen Inc. continued to publish and own the Canadian website and related product information. The change represented a rebranding and organizational positioning decision rather than the immediate disappearance of the Canadian legal entity or its product portfolio. Janssen Canada has also played a role in the Canadian introduction of important newer therapies. Examples include the conditional Health Canada authorization of RYBREVANT for selected patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer, the authorization of CARVYKTI for eligible patients with relapsed or refractory multiple myeloma, and later Canadian authorizations involving RYBREVANT, LAZCLUZE, and TREMFYA. During the COVID-19 pandemic, Janssen and Johnson & Johnson engaged with the Government of Canada regarding supply of the Ad26.COV2.S vaccine candidate, which was later authorized in Canada as the Janssen COVID-19 vaccine. The brand’s positioning combines science-led pharmaceutical innovation with Johnson & Johnson’s Credo-based emphasis on patient needs, ethical standards, collaboration, and access. Because the public-facing Canadian business is in transition from Janssen to Johnson & Johnson Innovative Medicine, both names remain relevant: Janssen identifies the historical pharmaceutical brand and legal operating company, while Johnson & Johnson Innovative Medicine is the current commercial identity used by the parent organization.
History
Janssen’s history begins with Dr. Paul Janssen, a Belgian physician and pharmacologist whose research-based pharmaceutical company became known for developing medicines in areas that were often underserved by conventional drug research. Janssen Pharmaceutica joined the Johnson & Johnson family in 1961. That transaction provided the scientific organization with the resources and international infrastructure of a major healthcare company while preserving the importance of pharmaceutical research and innovation within the combined group. The Janssen organization expanded internationally through a network of companies, research centers, licensing relationships, and commercial affiliates. Its work eventually covered oncology, immunology, neuroscience, infectious diseases, cardiopulmonary medicine, vaccines, and other specialty areas. The organization’s historical identity was associated with a broad portfolio of prescription medicines and with a research culture built around translating laboratory science into clinically useful therapies. In Canada, the Janssen business developed into a national pharmaceutical organization headquartered in Toronto. Canadian operations have included commercial distribution and sales, medical affairs, regulatory activities, clinical research, market access, patient-support services, and engagement with healthcare professionals and public institutions. The Canadian business has operated for more than 50 years. Earlier corporate structures included Janssen Pharmaceutica Canada and Janssen-Ortho. Janssen-Ortho Inc. was renamed Janssen Inc. in 2010, according to Canadian lobbying-registration records. The Canadian organization has historically served as the local interface between Johnson & Johnson’s international pharmaceutical network and Canada’s federal and provincial healthcare systems. It has submitted medicines for Health Canada review, supported evidence generation, worked with public and private payers, and communicated product information to physicians, pharmacists, patients, and caregivers. Johnson & Johnson’s Canadian supply-chain reporting indicates that Janssen Inc. does not manufacture medicines in Canada; instead, the Canadian entity supports sales and marketing for products made by Johnson & Johnson and external partners in other locations and imported into Canada. The portfolio has changed over time as medicines have lost exclusivity, new indications have been approved, and newer biologic, targeted, and cell-based therapies have entered the market. Canadian products have included treatments in oncology, immunology, neuroscience, pulmonary hypertension, cardiovascular and metabolic disease, infectious disease, and mental health. The business has also supported clinical trials and patient programs intended to improve the safe and effective use of medicines and to help patients navigate complex reimbursement systems. During the COVID-19 pandemic, Janssen and Johnson & Johnson worked with Canadian authorities regarding the Ad26.COV2.S vaccine candidate. The Canadian government announced an agreement in principle in August 2020, and Health Canada later authorized the vaccine in March 2021. The episode demonstrated the role of Janssen Canada as a regulatory, commercial, and public-health intermediary even when manufacturing occurred outside Canada. A significant corporate transition began in 2023, when Johnson & Johnson announced an updated global identity and stated that the Janssen pharmaceutical segment would progressively be renamed Johnson & Johnson Innovative Medicine. Canadian communications subsequently adopted the Johnson & Johnson Innovative Medicine name, while the legal entity Janssen Inc. remained responsible for the Canadian website and certain corporate activities. The transition reflects a move toward a unified Johnson & Johnson healthcare identity rather than a simple withdrawal from pharmaceutical activity. In 2024 and 2025, the Canadian organization continued announcing regulatory developments for products including CARVYKTI, RYBREVANT, LAZCLUZE, and TREMFYA. These launches and label expansions illustrate the current strategic emphasis on specialty medicines, precision treatment, immunology, oncology, and advanced therapies. Janssen Canada therefore remains historically recognizable as Janssen but is increasingly presented publicly as Johnson & Johnson Innovative Medicine Canada.
- 2025
LAZCLUZE and RYBREVANT authorized for first-line lung cancer treatment
[6]Health Canada authorized the combination of LAZCLUZE and RYBREVANT as a chemotherapy-free first-line treatment for eligible patients with EGFR-mutated advanced lung cancer.
- 2025
TREMFYA authorized for Crohn’s disease
[6]Health Canada authorized TREMFYA for adults with moderately to severely active Crohn’s disease.
- 2024
CARVYKTI authorized in Canada
[6]Health Canada authorized CARVYKTI for eligible patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy.
- 2024
RYBREVANT combination authorization expands
[6]Health Canada authorized RYBREVANT in combination with carboplatin and pemetrexed for first-line treatment of eligible patients with EGFR exon 20 insertion-mutated advanced lung cancer.
- 2023
Johnson & Johnson announces the transition from Janssen to Innovative Medicine
[3]Johnson & Johnson announced that its pharmaceutical segment would progressively adopt the Johnson & Johnson Innovative Medicine identity.
- 2022
RYBREVANT receives conditional Canadian authorization
[13]Health Canada issued a Notice of Compliance with Conditions for RYBREVANT for a defined population with EGFR exon 20 insertion-mutated non-small-cell lung cancer.
- 2021
Janssen COVID-19 vaccine authorized in Canada
[12]Health Canada authorized the Janssen COVID-19 vaccine for use in Canada.
- 2020
Agreement in principle for Canadian COVID-19 vaccine supply
[11]Janssen Inc. announced an agreement in principle with the Government of Canada concerning supply of the Ad26.COV2.S vaccine candidate.
- 2010
Janssen-Ortho Inc. becomes Janssen Inc.
[5]Canadian lobbying-registration records identify a 2010 name change from Janssen-Ortho Inc. to Janssen Inc.
- 1995
Janssen-Ortho is formed in Canada
[10]Ortho Pharmaceutical Canada merged with Janssen Pharmaceutica Canada to form Janssen-Ortho in Canada.
Products and positioning
Research-based pharmaceutical and innovative-medicine organization focused on serious and complex diseases, specialty care, patient access, and science-led healthcare innovation.
Oncology
DARZALEX
DARZALEX is a daratumumab-based treatment used in multiple myeloma. It is part of Janssen’s hematology-oncology portfolio and has been developed in several formulations and treatment combinations for patients with plasma-cell malignancies.
Oncology
ERLEADA
ERLEADA is the brand name for apalutamide, an androgen-receptor inhibitor used in prostate-cancer treatment. It represents Janssen’s focus on targeted and hormonally mediated cancer therapies.
Hematology-oncology
IMBRUVICA
IMBRUVICA is the brand name for ibrutinib, a Bruton’s tyrosine kinase inhibitor used in selected blood cancers. The product has been a significant component of Janssen’s Canadian hematology portfolio and has been studied in combination and fixed-duration regimens.
Immunology
STELARA
STELARA is an immunology biologic based on ustekinumab. It is used for selected immune-mediated diseases and has historically been associated with Janssen’s gastroenterology, dermatology, and rheumatology activities.
Immunology
TREMFYA
TREMFYA is guselkumab, an interleukin-23 pathway inhibitor. In Canada, its use has included immune-mediated conditions, with a 2025 authorization for adults with moderately to severely active Crohn’s disease.
Oncology · 2022
RYBREVANT
RYBREVANT is amivantamab, a fully human bispecific antibody targeting pathways relevant to EGFR-driven non-small-cell lung cancer. Health Canada authorized it for defined patients with EGFR exon 20 insertion mutations, with later Canadian authorizations expanding combination use.
Cell therapy · 2024
CARVYKTI
CARVYKTI is ciltacabtagene autoleucel, a B-cell maturation antigen-directed CAR-T cell therapy for eligible patients with relapsed or refractory multiple myeloma. Its Canadian authorization reflects Janssen’s participation in advanced, individualized cancer treatment.
Neuroscience and mental health
SPRAVATO
SPRAVATO is esketamine nasal spray, a Janssen neuroscience product developed for selected patients with treatment-resistant depression and related clinical uses subject to Canadian authorization and prescribing requirements.
Neuroscience
CONCERTA
CONCERTA is an extended-release methylphenidate medicine used in the treatment of attention-deficit/hyperactivity disorder. It is part of the historical Janssen neuroscience and mental-health portfolio.
Oncology
ZYTIGA
ZYTIGA is abiraterone acetate, an androgen-biosynthesis inhibitor used in prostate-cancer treatment. It has been one of the recognizable oncology products associated with Janssen’s Canadian commercial portfolio.
Vaccines · 2021
Janssen COVID-19 vaccine
The Janssen COVID-19 vaccine, based on the Ad26.COV2.S adenovirus platform, was developed by Johnson & Johnson and authorized in Canada during the COVID-19 pandemic. The Canadian organization supported government supply and regulatory communications.
Brand decisions
2025
Launch of LAZCLUZE with RYBREVANT in CanadaProduct launchBackground
Johnson & Johnson pursued a chemotherapy-free targeted treatment strategy for patients with EGFR-mutated advanced non-small-cell lung cancer.
Action taken
Health Canada authorized LAZCLUZE in combination with RYBREVANT as a first-line treatment for eligible patients.
Aftermath
The authorization strengthened the organization’s precision-oncology portfolio and broadened its Canadian lung-cancer offering.
2024
Expansion of RYBREVANT use with chemotherapyProduct launchBackground
Janssen pursued additional Canadian treatment options for patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer, a molecularly defined and historically underserved population.
Action taken
Health Canada authorized RYBREVANT in combination with carboplatin and pemetrexed for eligible previously untreated patients.
Aftermath
The authorization expanded the Canadian role of RYBREVANT from a later-line targeted treatment into a first-line combination option for a defined lung-cancer population.
2023
Transition from Janssen to Johnson & Johnson Innovative MedicineStrategyBackground
Johnson & Johnson sought a more unified corporate identity after separating its consumer-health activities and emphasizing its healthcare businesses. The company stated that the pharmaceutical segment historically known as Janssen would progressively use the Johnson & Johnson Innovative Medicine name.
Action taken
The Canadian pharmaceutical organization adopted Johnson & Johnson Innovative Medicine in public-facing communications while Janssen Inc. continued as the legal entity responsible for the Canadian website and operations.
Aftermath
The change created a dual identity in Canada: Janssen remained an important historical and legal reference, while Johnson & Johnson Innovative Medicine became the current commercial and organizational designation.
2020
Canadian COVID-19 vaccine supply agreementProduct launchBackground
During the COVID-19 pandemic, Canada sought access to multiple vaccine platforms before regulatory authorization and production arrangements were finalized.
Action taken
Janssen Inc. announced an agreement in principle with the Government of Canada to supply doses of the Ad26.COV2.S vaccine candidate if development succeeded and Health Canada authorized the product.
Aftermath
The vaccine was subsequently authorized in Canada in 2021, adding a pandemic vaccine to the Canadian Janssen portfolio.
Recent events
Reported
FDA approves Carvykti for advanced multiple myeloma[14]
The FDA approved ciltacabtagene autoleucel (Carvykti) to treat adults with relapsed or refractory multiple myeloma who have received four or more previous lines of therapy, including specified drug classes.
Reported
Novadiscovery expands collaboration with Janssen[15]
Novadiscovery announced an expansion of its collaboration with Janssen, applying its JINKO clinical trial simulation platform to expand an existing lung cancer model for Janssen’s market access and global medical affairs strategies.
Reported
Catalent and Janssen expand vaccine manufacturing partnership[16]
Catalent announced an expanded partnership with Janssen to increase manufacturing capacity for Janssen's COVID-19 vaccine at Catalent's Anagni, Italy facility, including vial-filling, inspection, labeling, and packaging services. An additional high-speed vial-filling line was expected to be operational in the fourth quarter of 2021.
- Unconfirmed
Reported
Janssen and Sema4 collaborate on cancer trial recruitment[17]
Janssen teamed up with Sema4 to use Sema4's genomic testing and data analytics platform to identify patients for Janssen cancer trials.
Reported
Johnson & Johnson expands US coronavirus research collaboration[18]
Johnson & Johnson expanded its collaboration with BARDA and the US Department of Health & Human Services to screen existing antiviral molecules for compounds that may work against COVID-19. Janssen will also work with Belgium's Rega Institute for Medical Research as part of the expanded collaboration.
Sources18 sources
- 1About us - Johnson & Johnson Innovative Medicine Canadajnj.com
- 2Introducing Johnson & Johnson Innovative Medicine - Canadajnj.com
- 3Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identityjnj.com
- 4Canadian Fighting Against Forced Labour and Child Labour in Supply Chains Act Annual Reportjnj.com
- 5Janssen Inc. Responsible Officer and Name Change Historylobbycanada.gc.ca
- 6Janssen Canada News Centrejnj.com
- 7Our medicines - Johnson & Johnson Innovative Medicine Canadajnj.com
- 8Janssen Canada Wikidata entrywikidata.org
- 9Janssen Pharmaceutica joins Johnson & Johnsonjnj.com
- 10Ortho Pharmaceutical Canada merges with McNeil Pharmaceutical Canadaen.wikipedia.org
- 11Agreement in principle for Canadian COVID-19 vaccine supplyjnj.com
- 12Janssen COVID-19 vaccine authorized in Canadacanada.ca
- 13RYBREVANT receives conditional Canadian authorizationjnj.com
- 14FDA批准Carvykti用于晚期多发性骨髓瘤healio.com
- 15Novadiscovery扩大与Janssen的合作finance.yahoo.com
- 16Catalent与Janssen扩大疫苗生产合作prweb.com
- 17Janssen与Sema4合作支援癌症试验招募fiercebiotech.com
- 18强生扩大美国新冠病毒研究合作pmlive.com
Cite this profile: Cite the canonical profile. /brand-wiki/janssen · Editorial policy · How profiles are compiled